Phase 1b/2a clinical trial of NVG-291 to include individuals with chronic and subacute spinal cord injuries Vancouver, British Columbia--(Newsfile Corp. - March 30, 2023) - NervGen Pharma Corp. (TSXV: ...
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort ...
In August, Dr. Mikol presented unblinded data from the SAD cohort of the Phase 1 clinical trial and interim blinded data from the MAD portion of the study at the 2022 Alzheimer's Association ...
During the 2022 fiscal year and 2023 to date, we have received proceeds of approximately CA$3.5 million from the exercise of stock options and common share purchase warrants. We announced pioneering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback